Cholera vaccines for the developing world

Human Vaccines

Volumn 4, Issue 2, 2008, Pages 165-169

  Lopez, Anna Lena ^a   Clemens, John D ^a   Deen, Jacqueline ^a   Jodar, Luis ^a  

^a International Vaccine Institute   (South Korea)

Author keywords

Cholera; Developing countries; Diarrhea; Vaccine; Vibrio

Indexed keywords

ANTIBIOTIC AGENT; CHOLERA VACCINE;

ANTIBIOTIC THERAPY; BACTERIAL STRAIN; BACTERIAL TRANSMISSION; CHOLERA; COST OF ILLNESS; DISEASE COURSE; DRUG EFFICACY; ENDEMIC DISEASE; EPIDEMIC; FATALITY; FOOD CONTAMINATION; HEALTH CARE COST; HEALTH CARE NEED; HEALTH CARE POLICY; HUMAN; IMMUNIZATION; IMMUNOGENICITY; INCIDENCE; INCUBATION TIME; INFECTION CONTROL; NOTE; ORAL REHYDRATION THERAPY; SANITATION; SINGLE DRUG DOSE; UNSPECIFIED SIDE EFFECT; VIBRIO CHOLERAE; WATER CONTAMINATION; WATER SUPPLY;

EID: 45849130175     PISSN: 15548600     EISSN: 15548619     Source Type: Journal    
DOI: 10.4161/hv.4.2.5122     Document Type: Note

References (66)

1. World Health Organization. Cholera vaccines. Wkly Epidemiol Rec 2001; 76:117-24.
2. World Health Organization. Cholera, 2006. Wkly Epidemiol Rec 2007; 82:273-84.
3. Ramarmurthy T, Garg S, Sharma R, Bhattacharya SK, Nair GB, Shimada T, Karasawa T, Kurazono H, Pal A, Takeda Y. Emergence of a novel strain of Vibrio cholerae with epidemic potential in southern and eastern India. Lancet 1993; 341:703-4.
4. Cholera Working Group, International Centre of Diarrhoeal Disease Research, Bangladesh. Large epidemic of cholera like disease in Bangladesh caused by Vibrio cholerae O19 synonym Bengal. Lancet 1993; 342:387-90.
5. Hirschhorn N, Chowdhury AK, Lindenbaum J. Cholera in pregnant women. Lancet 1969; 1:1230-2.
6. Clemens JD, Sack DA, Harris JR. Chakraborty J, Khan MR, Stanton BF, et al. Impact of B subunit killed whole-cell and killed whole-cell-only oral vaccines against cholera upon treated diarrheal illness and mortality in an area endemic for cholera. Lancet 1988; 18:1375-9.
7. Sack RB, Siddique AK, Longini Jr IM, Nizam A, Yunus M, Islam MS, Morris Jr JG, Ali A, Huq A, Nair GB, Qadri F, Faruque SM, Sack DA, Colwell RR. A 4-year study of the epidemiology of Vibrio cholerae in four rural areas of Bangladesh. J Infect Dis 2003; 187:96-101.
8. Deen JL, von Seidlein L, Sur D, Agtini M, Lucas MES, Lopez AL, Ali M, Clemens JD. The high burden of cholera in children: Comparison of incidence from endemic areas in Asia and Africa; In press.
9. Sack D, Sack R, Nair G, Siddique A. Cholera. Lancet 2004; 363:223-33.
10. Connolly MA, Gayer M, Ryan MJ, Salama P, Spiegel P, Heymann DL. Communicable diseases in complex emergencies: Impact and challenges. Lancet 2004; 364:1974-83.
11. World Health Organization. WHO Report on global surveillance of epidemic-prone infectious diseases. Geneva World Health Organization 2000, (WHO/CDS/CSR/ISR/2000.1).
12. World Health Organization. Global defence against the infectious disease threat. Geneva World Health Organization 2003, (WHO/CDS/2003.15).
13. Griffith DC, Kelly-Hope LA, Miller MA. Review of reported cholera outbreaks worldwide, 1995-2005. Am J Trop Med Hyg 2006; 75:973-7.
14. World Health Organization. Cholera vaccines: A new public health tool? Report of a meeting, Geneva, 10-11 December 2002. Geneva World Health Organization 2004, (CDS/ CPE/ZFK/2004.5).
15. Committee on Emerging Social Issues, United Nations Economic and Social Council. Health and development: Selected issues: SARS and other epidemics: Lessons for public health. Economic and Social Commission for Asia and the Pacific. Bangkok, Thailand: 2003:4-6, (Document No.: E/ESCAP/CESI/6 2003).
16. Deen JL, von Seidlein L, Clemens JD. Multidisciplinary studies of disease burden in the Diseases of the Most Impoverished Programme. J Health Popul Nutr 2004; 22:232-9.
17. Deen J, Clemens. Antimicrobial therapy for cholera. Lancet 2005; 366:1054-5.
18. th Annual Meeting of the US-Japan Cooperative Medical Sciences Panel on Cholera and other Bacterial Enteric Infections, 2005.
19. Pach A, Santoso SS, Watuyo I, Han OP, Rifkin M, Park JK, DeRoeck D, Stanton B, Clemens J. Gender differences in perceptions of cholera and interest in cholera vaccination in two slum communities of North Jakarta, Indonesia; In press.
20. Lucas ME, Jeuland M, Deen J, Lazaro N, MacMahon M, Nyamete A, Barreto A, von Seidlein L, Cumbane A, Songane FF, Whittington D. Private demand for cholera vaccines in Beira, Mozambique. Vaccine 2007; 25:2599-609.
21. DeRoeck D, Clemens JD, Nyamete A, Mahoney RT. Policymakers' views regarding the introduction of new-generation vaccines against typhoid fever, shigellosis and cholera in Asia. Vaccine 2005; 23:2762-74.
22. Sack DA, Sack RB, Chaignat CL. Getting serious about cholera. N Engl J Med 2006; 355:649-51.
23. Hutton G, Haller L. Evaluation of the costs and benefits of water and sanitation improvements at the global level. Geneva: World Health Organization, 2004:(WHO/SDE/ WSH/04.04).
24. Clemens JD, Sack DA, Harris JR, Chakraborty J, Khan MR, Stanton BF, Kay BA, Khan MU, Yunus M, Atkinson W, Svennerholm AM, Holmgren J. Field trial of oral cholera vaccines in Bangladesh. Lancet 1986; 2:124-7.
25. Sanchez JL, Vasquez B, Begue RE, Meza R, Castellares G, Cabezas C, Watts DM, Svennerholm AM, Sadoff JC, Taylor DN. Protective efficacy of oral whole-cell/recombinant-B-subunit cholera vaccine in Peruvian military recruits. Lancet 1994; 344:1273-6.
26. Clemens JD, Sack DA, Harris JR, Van Loon F, Chakraborry J, Ahmed F, Rao MR, Khan MR, Yunus M, Huda N, Stanton BF, Kay BA, Walter S, Eeckels R, Svennerholm AM, Holmgren J. Field trial of oral cholera vaccines in Bangladesh: Results from three-year follow-up. Lancet 1990; 335:270-3.
27. Legros D, Paquet C, Perea W, Marty I, Mugisha N, Royer H, et al. Mass vaccination with a two-dose oral cholera vaccine in a refugee camp. Bull World Health Org 1999; 77:837-42.
28. Lucas ME, Deen JL, von Seidlein L, Wang XY, Ampuero J, Puri M, Ali M, Ansaruzzaman M, Amos J, Macuamule A, Cavailler P, Guerin PJ, Mahoudeau C, Kahozi-Sangwa P, Chaignat CL, Barreto A, Songane FF, Clemens JD. Effectiveness of mass oral cholera vaccination in Beira, Mozambique. N Engl J Med 2005; 352:757-67.
29. Ali M, Emch M, von Seidlein L, Yunus M, Sack DA Rao M, Holmgren J, Clemens JD. Herd immunity conferred by killed oral cholera vaccines in Bangladesh: A reanalysis. Lancet 2005; 366:44-9.
30. Thungapathra M, Sharma C, Gupta N, Ghosh RK, Mukhopadhyay A, Koley H, Nair GB, Ghosh A Construction of a recombinant live oral vaccine from a non-toxigenic strain of Vibrio cholerae O1 serotype inaba biotype El Tor and assessment of its reactogenicity and immunogenicity in the rabbit model. Immunol Lett 1999; 68:219-27.
31. Kotloff KL, Wasserman SS, O'Donnell S, Losonsky GA, Cryz SJ, Levine MM. Safety and immunogenicity in North Americans of a single dose of live oral cholera vaccine CVD 103-HgR: Results of a randomized, placebo-controlled, double-blind crossover trial. Infect Immun 1992; 60:4430-2.
32. Cryz Jr SJ, Levine MM, Losonsky G, Kaper JB, Althaus B. Safety and immunogenicity of a booster dose of Vibrio cholerae CVD 103-HgR live oral cholera vaccine in Swiss adults. Infect Immun 1992; 9:3916-7.
33. Gotuzzo E, Butron B, Seas C, Penny M, Ruiz R, Losonsky G, Lanata CF, Wasserman SS, Salazar E, Kaper JB, Cryz S, Levine MM. Safety immunogenicity and excretion pattern of single-dose live oral cholera vaccine CVD 103-HgR in Peruvian adults of high and low socioeconomic levels. Infect Immun 1993; 61:3994-7.
34. Suharyono, Simanjuntak C, Witham N, Punjabi N, Heppner DG, Losonsky G, Totosudirjo H, Rifai AR, Clemens J, Lim YL, et al. Safety and immunogenicity of single-dose live oral cholera vaccine CVD 103-HgR in 5-9-year-old Indonesian children. Lancet 1992; 340:689-94.
35. Simanjuntak CH, O'Hanley P, Punjabi NH, Noriega F, Pazzaglia G, Dykstra P, Kay B, Suharyono, Budiarso A, Rifai AR, et al. Safety, immunogenicity, and transmissibility of single-dose live oral cholera vaccine strain CVD 103-HgR in 24- to 59-month-old Indonesian children. J Infect Dis 1993; 168:1169-76.
36. Perry RT, Plowe CV, Koumare B, Bougoudogo F, KotloffKL, Losonsky GA Wasserman SS, Levine MM. A single dose of live oral cholera vaccine CVD 103-HgR is safe and immunogenic in HIV-infected and HIV-noninfected adults in Mali. Bull World Health Organ 1998; 76:63-71.
37. Tacket CO, Cohen MB, Wasserman SS, Losonsky G, Livio S, Kotloff K, Edelman R, Kaper JB, Cryz SJ, Giannella RA, Schiff G, Levine MM. Randomized, double-blind, placebo-controlled, multicentered trial of the efficacy of a single dose of live oral cholera vaccine CVD 103-HgR in preventing cholera following challenge with Vibrio cholerae O1 El for inaba three months after vaccination. Infect Immun 1999; 67:6341-5.
38. Richie EE, Punjabi NH, Sidharta YY, Peetosutan KK, Sukandar MM, Wasserman SS, Lesmana MM, Wangsasapurra FF, Pandam SS, Levine MM, O'Hanley PP, Cryz SJ, Simanjuntak CH. Efficacy trial of single-dose live oral cholera vaccine CVD 103-HgR in North Jakarta, Indonesia, a cholera-endemic area. Vaccine 2000; 18:2399-410.
39. Calain P, Chaine JP, Johnson E, Hawley ML, O'Leary MJ, Ositani H, Chaignat CL. Can oral cholera vaccination play a role in controlling a cholera outbreak? Vaccine 2004; 22:2444-51.
40. Trach DD, Clemens JD, Ke NT, et al. Field trial of a locally produced, killed, oral cholera vaccine in Viet Nam. Lancet 1997; 349:231-5.
41. Trach DD, Cam PD, Ke NT, et al. Investigations into the safety and immunogenicity of a killed oral cholera vaccine developed in Viet Nam. Bull World Health Organ 2002; 80:2-8.
42. Thiem VD, Deen JL, von Seidlein L, Canh do G, Aim DD, Park JK, Ali M, Danovaro-Holliday MC, Son ND, Hoa NT, Holmgren J, Clemens JD. Long-term effectiveness against cholera of oral killed whole-cell vaccine produced in Vietnam. Vaccine 2006; 24:4297-303.
43. Anh DD, Canh do G, Lopez AL, Thiem VD, Long PT, Son NH, Deen J, von Seidlein L, Carbis R, Han SH, Shin SH, Arrridge S, Holmgren J, Clemens J. Safety and immunogenicity of a reformulated Vietnamese bivalent killed, whole-cell, oral cholera vaccine in adults. Vaccine 2007; 25:1149-55.
44. Qadri F, Ahmed T, Wahed MA et al. Suppressive effect of zinc on antibody response to cholera toxin in children given the killed, B-subunit, whole-cell oral cholera vaccine. Vaccine 2004; 22:416-21.
45. Taylor DN, Killeen KP, Hack DC, Kenner JR, Coster TS, Beattie DT, Ezzell J, Hyman T, Trofa A, Sjogren MH, et al. Development of a live, oral, attenuated vaccine against E1 Tor cholera. J Infect Dis 1994; 170:1518-23.
46. Kenner JR, Coster TS, Taylor DN, Trofa AF, Barrera-Oro M, Hyman T, Adams JM, Beattie DT, Killeen KP, Spriggs DR, et al. Peru-15, an improved live attenuated oral vaccine candidate for Vibrio cholerae O1. J Infect Dis 1995; 172:1126-9.
47. Sack DA Sack RB, Shimko J, Gomes G, O'Sullivan D, Metcalfe K, Spriggs D. Evaluation of Peru-15, a new live oral vaccine for cholera, in volunteers. J Infect Dis 1997; 176:201-5.
48. Cohen MB, Giannella RA, Bean J, Taylor DN, Parker S, Hoeper A, Wowk S, Hawkins J, Kochi SK, Schiff G, Killeen KP. Randomized, controlled human challenge study of the safety, immunogenicity, and protective efficacy of a single dose of Peru-15, a live attenuated oral cholera vaccine. Infect Immun 2002; 70:1965-70.
49. Qadri F, Chowdhury MI, Faruque SM, Salam MA Ahmed T, Begum YA Saha A, Alam MS, Zaman K, Seidlein LV, Park E, Killeen KP, Mekalanos JJ, Clemens JD, Sack DA Peru-15 study group: Randomized, controlled study of the safety and immunogenicity of Peru-15, a live attenuated oral vaccine candidate for cholera, in adult volunteers in Bangladesh. J Infect Dis 2005; 192:573-9.
50. Qadri F, Chowdhury MI, Faruque SM, Salam MA, Ahmed T, Begum YA, Saha A, Al Tarique A, Seidlein LV, Park E, Killeen KP, Mekalanos JJ, Clemens JD, Sack DA The PXV Study Group: Peru-15, a live attenuated oral cholera vaccine, is safe and immunogenic in Bangladeshi toddlers and infants. Vaccine 2007; 25:231-8.
51. Garcia L, Jidy MD, Garcia H, Rodriguez BL, Fernandez R, Ano G, Cedre B, Valmaseda T, Suzarte E, Ramirez M, Pino Y, Campos J, Menendez J, Valeta R, Gonzalez D, Gonzalez I, Perez O, Serrano T, Lastre M, Miralles F, Del Campo J, Maestre JL, Perez JL, Talavera A, Perez A Marrero K, Ledon T, Fando R. The vaccine candidate Vibrio cholerae 638 is protective against cholera in healthy volunteers. Infect Immun 2005; 73:3018-24.
52. Tacket CO, Kotloff KL, Losonsky G, Nataro JP, Michalski J, Kaper JB, Edelman R, Levine MM. Volunteer studies investigating the safety and efficacy of live oral El Tor Vibrio cholerae O1 vaccine strain CVD 111. Am J Trap Med Hyg 1997; 56:533-7.
53. Taylor DN, Sanchez JL, Castro JM, Lebron C, Parrado CM, Johnson DE, Tacket CO, Losonsky GA Wasserman SS, Levine MM, Cryz SJ. Expanded safety and immunogenicity of a bivalent, oral, attenuated cholera vaccine, CVD 103-HgR plus CVD 111, in United States military personnel stationed in Panama. Infect Immun 1999; 67:2030-4.
54. Jertborn M, Svennerholm AM, Holmgren J. Intestinal and systemic immune responses in humans after immunization with a bivalent B-subunit-0l/0-139 whole cell cholera vaccine. Vaccine 1996; 14:1459-65.
55. Thungapathra M, Sharma C, Gupta N, Ghosh RK, Mukhopadhyay A, Koley H, Nair GB, Ghosh A Construction of a recombinant live oral vaccine from a non-toxigenic strain of Vibrio cholerae O1 serotype Inaba biotype El Tor and assessment of its reactogenicity and immunogenicity in the rabbit model. Immunol Lett 1999; 68:219-27.
56. Liang W, Wang S, Yu F, Zhang L, Qi G, Liu Y, Gao S, Kan B. Construction and evaluation of a safe, live, oral Vibrio cholerae vaccine candidate, IEM108. Infect Immun 2003; 71:5498-504.
57. Liu G, Yan M, Liang W, Qi G, Liu Y, Gao S, Kan B. Resistance of the cholera vaccine candidate IEM108 against CTXPhi infection. Vaccine 2006; 24:1749-55.
58. Tacket CO, Losonsky G, Nataro JP, Comstock L, Michalski J, Edelman R, Kaper JB, Levine MM. Initial clinical studies of CVD 112 Vibrio cholerae 0139 live oral vaccine: Safety and efficacy against experimental challenge. J Infect Dis 1995; 172:883-6.
59. Coster TS, Killeen KP, Waldor MK, Beattie DT, Spriggs DR, Kenner JR, Trofa A, Sadoff JC, Mekalanos JJ, Taylor DN. Safety, immunogenicity, and efficacy of live attenuated Vibrio cholerae 0139 vaccine prototype. Lancet 1995; 345:949-52.
60. Gupta RK, Taylor DN, Bryla DA, Robbins JB, Szu SC. Phase 1 evaluation of Vibrio cholerae O1, serotype Inaba, polysaccharide-cholera toxin conjugares in adult volunteers. Infect Immun 1998; 66:3095-9.
61. Dorlencourt F, Legros D, Paquer C, Neira M, Ivanoff B, Le Saout E. Effectiveness of mass vaccination with WC/rBS cholera vaccine during an epidemic in Adjumani district, Uganda. Bull World Health Organ 1999; 77:949-50.
62. World Health Organization. Use of the two-dose oral cholera vaccine in the context of a major natural disaster. Report of a mass vaccination campaign in Aceh province, Indonesia. Geneva: World Health Organization, 2005:(WHO/CDS/NTD/IDM/2006.1).
63. Cavailler P, Lucas M, Perroud V, McChesney M, Ampuero S, Guerin PJ, Legros D, Nierle T, Mahoudeau C, Lab B, Kahozi P, Deen JL, von Seidlein L, Wang XY, Puri M, Ali M, Clemens JD, Songane F, Baprista A, Ismael F, Barreto A, Chaignat CL. Feasibility of a mass vaccination campaign using a two-dose oral cholera vaccine in an urban cholera-endemic setting in Mozambique. Vaccine 2006; 24:4890-5.
64. Thiem VD, Hossain MM, Son ND, et al. Coverage and costs of mass immunization of an oral cholera vaccine in Vietnam. J Health Popul Nutr 2003; 4:304-8.
65. Murray J, McFarland DA Waldman RJ. Cost-effectiveness of oral cholera vaccine in a stable refugee population at risk for epidemic cholera and in a population with endemic cholera. Bull World Health Organ 1998; 76:343-52.
66. Oral cholera vaccine use in complex emergencies: What next? Report of a meeting, Cairo 14-16 December 2005 - Geneva World Health Organization 2006, (CDS/NTD/ IDM/2006.2).